Keros Therapeutics Inc. (NASDAQ:KROS) shares traded 5.23% higher at $53.75 on Wall Street last session.
KROS stock price is now 2.46% away from the 50-day moving average and 28.02% away from the 200-day moving average. The market capitalization of the company currently stands at $1.39B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
On October 18, 2022, Truist recently initiated its ‘Buy’ rating on the stock quoting a target price of $100, while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Lachey Jennifer, Chief Scientific Officer sold 46,034 shares of the company’s stock on Jul 15. The stock was sold for $1,381,020 at an average price of $30.00. Upon completion of the transaction, the Chief Scientific Officer now directly owns 95,100 shares in the company, valued at $5.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 13, Chief Scientific Officer Lachey Jennifer sold 1,916 shares of the business’s stock. A total of $57,480 was realized by selling the stock at an average price of $30.00. This leaves the insider owning 95,100 shares of the company worth $5.11 million. Insiders disposed of 93,270 shares of company stock worth roughly $5.01 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KROS stock. A new stake in Keros Therapeutics Inc. shares was purchased by DARWIN GLOBAL MANAGEMENT, LTD. during the first quarter worth $23,034,000. MILLENNIUM MANAGEMENT LLC invested $9,744,000 in shares of KROS during the first quarter. In the first quarter, WCM INVESTMENT MANAGEMENT, LLC acquired a new stake in Keros Therapeutics Inc. valued at approximately $4,469,000. ACUTA CAPITAL PARTNERS, LLC acquired a new stake in KROS for approximately $4,300,000. CASDIN CAPITAL, LLC purchased a new stake in KROS valued at around $3,494,000 in the second quarter. In total, there are 193 active investors with 85.30% ownership of the company’s stock.
Keros Therapeutics Inc. (NASDAQ: KROS) opened at $50.85 on Wednesday. During the past 12 months, Keros Therapeutics Inc. has had a low of $24.38 and a high of $68.29. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 21.30, and a quick ratio of 21.30. The fifty day moving average price for KROS is $52.46 and a two-hundred day moving average price translates $41.99 for the stock.
The latest earnings results from Keros Therapeutics Inc. (NASDAQ: KROS) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.92, beating analysts’ expectations of -$1.23 by 0.31. This compares to -$0.29 EPS in the same period last year.
Keros Therapeutics Inc.(KROS) Company Profile
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
